1,516
Participants
Start Date
October 31, 2010
Primary Completion Date
September 30, 2013
Study Completion Date
September 30, 2013
Data collection
New onset of cases for endpoints of interest in the targeted population will be identified from ambulatory and inpatient electronic administrative data and will be confirmed by blinded review of the medical record by an Endpoint Adjudication Committee (EAC) that will confirm the AID case and will assess whether the onset of disease falls within the observation period. Fibromyalgia and psoriasis, for which a high number of cases are expected, will be identified from the electronic administrative data only.
GSK Investigational Site, Wilmington
Lead Sponsor
GlaxoSmithKline
INDUSTRY